Literature DB >> 10742282

The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors.

D Smart1, J C Jerman, S J Brough, W A Neville, F Jewitt, R A Porter.   

Abstract

The pharmacology of the orexin-like peptides, hypocretin-1 and hypocretin-2, was studied in Chinese hamster ovary (CHO) cells stably expressing orexin-1 (OX(1)) or orexin-2 (OX(2)) receptors by measuring intracellular calcium ([Ca(2+)](i)) using Fluo-3AM. Orexin-A and orexin-B increased [Ca(2+)](i) in CHO-OX(1) (pEC(50)=7. 99+/-0.05 and 7.00+/-0.10 respectively, n=8) and CHO-OX(2) (pEC(50)=8.30+/-0.05 and 8.21+/-0.07 respectively, n=5). However, hypocretin-1 and hypocretin-2 were markedly less potent, with pEC(50) values of 5.31+/-0.04 and 5.41+/-0.04 respectively in CHO-OX(2) cells (n=5). In CHO-OX(1) cells 10 microM hypocretin-1 only elicited a 37.5+/-3.4% response whilst 10 microM hypocretin-2 elicited a 18.0+/-2.1% response (n=8). Desensitisation of OX(1) or OX(2) with orexin-A (100 nM) abolished the response to orexin-A (10 nM) and the hypocretins (10 microM), but not to UTP (3 microM). In conclusion, the hypocretins are only weak agonists at the orexin receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742282      PMCID: PMC1571990          DOI: 10.1038/sj.bjp.0703257

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Cardiovascular regulatory actions of the hypocretins in brain.

Authors:  W K Samson; B Gosnell; J K Chang; Z T Resch; T C Murphy
Journal:  Brain Res       Date:  1999-06-12       Impact factor: 3.252

2.  Orexins: a new family of neuropeptides.

Authors:  D Smart
Journal:  Br J Anaesth       Date:  1999-11       Impact factor: 9.166

Review 3.  Molecular mechanisms of membrane receptor desensitization.

Authors:  M J Lohse
Journal:  Biochim Biophys Acta       Date:  1993-11-07

4.  Neurons containing hypocretin (orexin) project to multiple neuronal systems.

Authors:  C Peyron; D K Tighe; A N van den Pol; L de Lecea; H C Heller; J G Sutcliffe; T S Kilduff
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

Review 5.  Obesity and the hypothalamus: novel peptides for new pathways.

Authors:  J S Flier; E Maratos-Flier
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

6.  Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR.

Authors:  D Smart; J C Jerman; S J Brough; S L Rushton; P R Murdock; F Jewitt; N A Elshourbagy; C E Ellis; D N Middlemiss; F Brown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  Hypothalamic hypocretin (orexin): robust innervation of the spinal cord.

Authors:  A N van den Pol
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

8.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

9.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

10.  Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin.

Authors:  A N van den Pol; X B Gao; K Obrietan; T S Kilduff; A B Belousov
Journal:  J Neurosci       Date:  1998-10-01       Impact factor: 6.167

  10 in total
  10 in total

1.  SB-334867-A: the first selective orexin-1 receptor antagonist.

Authors:  D Smart; C Sabido-David; S J Brough; F Jewitt; A Johns; R A Porter; J C Jerman
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats.

Authors:  S G Nair; S A Golden; Y Shaham
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

3.  Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats.

Authors:  Y Fan; E Jiang; T Hahka; Q H Chen; J Yan; Z Shan
Journal:  Acta Physiol (Oxf)       Date:  2017-10-23       Impact factor: 6.311

4.  Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity.

Authors:  Griselda Moreno; Mario Perelló; Rolf C Gaillard; Eduardo Spinedi
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

5.  Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats.

Authors:  Luyi Zhou; Rachel J Smith; Phong H Do; Gary Aston-Jones; Ronald E See
Journal:  Neuropharmacology       Date:  2012-08-07       Impact factor: 5.250

6.  Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones.

Authors:  Marco van den Top; Matthew F Nolan; Kevin Lee; Peter J Richardson; Ruud M Buijs; Ceri H Davies; David Spanswick
Journal:  J Physiol       Date:  2003-04-17       Impact factor: 5.182

Review 7.  Role of Orexin-A in Hypertension and Obesity.

Authors:  Roberta Imperatore; Letizia Palomba; Luigia Cristino
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 8.  The use of the reinstatement model to study relapse to palatable food seeking during dieting.

Authors:  Donna J Calu; Yu-Wei Chen; Alex B Kawa; Sunila G Nair; Yavin Shaham
Journal:  Neuropharmacology       Date:  2013-05-06       Impact factor: 5.250

9.  Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network.

Authors:  Bin Wang; Zhi-Bing You; Roy A Wise
Journal:  Biol Psychiatry       Date:  2009-02-28       Impact factor: 13.382

10.  Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction.

Authors:  Luyi Zhou; Wei-Lun Sun; Ronald E See
Journal:  Pharmaceuticals (Basel)       Date:  2011-06-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.